General
Preferred name
TAZOBACTAM
Synonyms
Tazobactam acid ()
CL-298741 ()
YTR-830H ()
Tazobactamum ()
Tazobac / Tazocillin ()
TAZOBACTAM SODIUM ()
Tazobactam (sodium) ()
Tazobactam acid, Tazobactamum ()
Tazobactam acid Sodium, Tazobactamum Sodium ()
CL 298,741 ()
NSC-759887 ()
Tazobactum sodium ()
Tazobactam sodium component of zerbaxa ()
Tazocillin ()
CL-307579 ()
CL 307,579 ()
Tazobactam (as sodium) ()
Tazobactam sodium component of zosyn ()
Tazobactam sodium salt ()
Tazobactam (sodium salt) ()
P&D ID
PD009452
CAS
89786-04-9
89785-84-2
Tags
available
covalent binder
drug
Approved by
EMA
FDA
First approval
1993
Drug indication
infection
Bacterial infection
Urinary tract infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Tazobactam (CXA-201) is a β-lactamase inhibitor with antibacterial activity . It is used alongside β-lactam-containing antibacterials to reduce their lactamase-induced degradation. Chemically tazobactam is a penicillin derivative, that binds as an irreversible inhibitor of β-lactamase. (GtoPdb)
PRICE 29
PHARMACODYNAMICS Tazobactam inhibits the action of bacterial beta-lactamase producing organisms, which are normally resistant to beta-lactam antibiotics. This augments the effects of antibiotics which would otherwise not be effective in treating certain infections. These antibiotics contain a beta-lactam ring in their chemical structure, which is destroyed by beta-lactam resistant organisms.[A179272] When combined with other antibiotics, a variety of infections, including serious and life-threatening infections may be treated.[FDA label,L4417]
MOA Tazobactam broadens the spectrum of piperacillin[L4417] and ceftolozane[FDA label] by making them effective against organisms that express beta-lactamase and would normally degrade them. This occurs through the irreversible inhibition of beta-lactamase enzymes. In addition, tazobactam may bind covalently to plasmid-mediated and chromosome-mediated beta-lactamase enzymes. Tazobactam is predominantly effective against the OHIO-1, SHV-1, and TEM groups of beta-lactamases, but may also inhibit other beta-lactamases.[A179386,A179389,A179395]; ; Tazobactam shows little antibacterial activity by itself, and for this reason, is generally not administered alone.[FDA label];
ROE Tazobactam and its metabolite are mainly eliminated by the kidneys with about 80% of the administered dose eliminated as unchanged drug. The remaining drug is excreted as a single metabolite.[L4417]
HALF-LIFE Piperacillin-tazobactam; ; After a single dose in healthy volunteers, the plasma half-life of piperacillin and tazobactam was in the range of 0.7 to 1.2 hours.[L4417]; ; Ceftolozane-tazobactam; ; 0.91-1.03 hours [FDA label]
METABOLISM Tazobactam is mainly metabolized to M1, an inactive metabolite.[L4417]; Hydrolysis occurs on the beta-lactam ring to form M1 (the inactive metabolite).[FDA label,A179368]; ;
ABSORPTION Tazobactam is coadministered with piperacillin or ceftolozane, pharmacokinetic information will be provided for these combinations.; ; **Piperacillin-tazobactam**; ; Peak plasma concentrations occur immediately after the completion of intravenous infusion. Following several doses of piperacillin-tazobactam infusions every 6 hours, peak concentrations were similar to those that were measured after the initial dose.[L4417]; ; **Ceftolozane-piperacillin**; ; AUC: 24.4-25 mcg•h/mL; ; Peak concentrations are reached on day 1 after the first dose and range from 18 to 18.4 mcg/mL.[FDA label];
INDICATION Tazobactam is used in combination with piperacillin or ceftolozane to broaden the spectrum of piperacillin antibacterial action, treating susceptible infections. As with any other antibiotic, tazobactam should only be used for infections that are either proven or strongly suspected to be susceptible to the tazobactam containing drug.; ; **Tazobactam-piperacillin**; ; When combined with piperacillin, it is used to treat a variety of infections, including those caused by aerobic and facultative gram-positive and gram-negative bacteria, in addition to gram-positive and gram-negative anaerobes. Some examples of infections treated with piperacillin-tazobactam include cellulitis, diabetic foot infections, appendicitis, and postpartum endometritis infections.[L4417] Certain gram-negative bacilli infections with beta-lactamase producing organisms cannot be treated with piperacillin-tazobactam, due to a gene mutation conferring antibiotic resistance.[A179266]; ; **Tazobactam-ceftolozane**; ; Tazobactam-ceftolozane combined with metronidazole is used to treat complicated urinary tract infections (UTI) and complicated intra-abdominal infections, as well as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.[FDA label]. This combination increases efficacy against infections with gram-negative bacilli.[A7657]
TOXICITY **Overdose**; ; Post-marketing reports have been made of overdose cases with piperacillin/tazobactam. Nausea, vomiting, and diarrhea are frequent manifestations of an overdose. Neuromuscular excitability or seizures may also occur with high intravenous doses or renal failure. There is no specific antidote. Provide supportive measures in case of an overdose. Anticonvulsive agents may be indicated when neuromuscular excitability or seizures occur. If anaphylaxis occurs, traditional measures should be taken to manage hypersensitivity (for example, adrenaline, antihistamines, corticosteroids, and oxygen/airway maintenance).[L6661] Similar measures should be taken after a ceftolozane-tazobactam overdose.[FDA label] Hemodialysis can be used to remove the drug from the circulation [FDA label,L4417].; ; **A note on nephrotoxicity**; ; Cases of life-threatening nephrotoxicity have been seen in critically ill patients receiving piperacillin-tazobactam. Alternative therapy and/or renal monitoring should be considered in critically ill patients.[L6664]; ; **Carcinogenesis/Mutagenesis**; ; Tazobactam tested negative for genotoxic effects in the Ames assay, an after in vitro chromosomal aberration and point mutation assay in the Chinese hamster, an various other assays.[FDA label]; ; **Use in pregnancy**; ; Tazobactam has been found cross the placenta in rats. No data on human studies are available, however, rat studies have shown no teratogenetic effects at doses 6-14 times the equivalent maximum recommended human dose.[L4417]; ; **Use in lactation**; ; There are no data on the presence of tazobactam in human breastmilk. No data are currently available on the effects of tazobactam on the infant, or how it affects milk production. Use clinical judgement and consider the maternal need for the drug and the benefits of breastfeeding the infant before administration during lactation.[L4417] Small concentrations of piperacillin-tazobactam have been found in the breastmilk and can lead to hypersensitivity in a breastfeeding infant. In some cases, breastfeeding may have to be discontinued temporarily.[L6661];
DESCRIPTION Tazobactam (CL-298741) is a potent ¦Â-lactamases inhibitor and penicillin antibiotic. Tazobactam has antibacterial activity. Tazobactam can be used for pneumonia research[1][2].
DESCRIPTION Tazobactam (YTR-830H) is an antibacterial penicillin derivative which inhibits the action of bacterial beta-lactamases. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
25
Cayman Chemical Bioactives
ChEMBL Approved Drugs
CovalentInDB
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
ZINC Tool Compounds
External IDs
286
Properties
(calculated by RDKit )
Molecular Weight
300.05
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
1
cLogP
-1.52
TPSA
122.46
Fraction CSP3
0.6
Chiral centers
3.0
Largest ring
5.0
QED
0.67
Structural alerts
1
Beta lactamase inhibition
Nuisance compounds
Custom attributes
(extracted from source data)
Target
antibiotic
Bacterial
β-Lactamase
Selection Antibiotics for Transfected Cell,¦Â-lactamase
Beta-lactamase
Indication
pneumonia
MOA
beta lactamase inhibitor
Biosynthetic Origin
Peptide (beta-Lactam)
Therapeutic Indication
Antibacterial
Therapeutic Class
Antimicrobial
Antiinfective Agents
Pathway
Microbiology/virology
Anti-infection
Source data